SCHEMBL2938241

SCHEMBL2938241

O=C1CN(Cc2ccncc2N2CCCCC2)C(=O)N1c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 1/20 0.35
PPARA Q07869 1/20 0.35
MAPT P10636 3/20 0.35
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.35
CACNA2D1 P54289 1/20 0.34
CACNA2D2 Q9NY47 1/20 0.34
TAS2R8 Q9NYW2 3/20 0.34
GALR2 O43603 1/20 0.33
MCHR1 Q99705 1/20 0.33
TRPC5 Q9UL62 1/20 0.33
MEN1 O00255 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
KMT2A Q03164 1/20 0.32
ENPP2 Q13822 1/20 0.32
POLB P06746 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2941164 0.91 ALDH1A1 (0.39) PPARDPPARATAS2R8MEN1KMT2A
SCHEMBL2944016 0.91 PRKDC (0.37) PPARDPPARAMAPTGAATAS2R8
SCHEMBL2938307 0.85 IGF1R (0.41) PPARDPPARATAS2R8ENPP2SCN9A
SCHEMBL2939136 0.84 TAS2R8 (0.38) PPARDPPARAMAPTTAS2R8MEN1
SCHEMBL2940706 0.84 PPARD (0.38) PPARDPPARAMAPTTAS2R8MEN1
SCHEMBL2938073 0.84 LMNA (0.45) PPARDPPARATAS2R8CYP2D6ENPP2
SCHEMBL2937246 0.84 EPHX2 (0.38) PPARDPPARAGAAHRH3EPHX2
SCHEMBL2938300 0.83 TAS2R8 (0.37) PPARDPPARATAS2R8ENPP2SCN9A
SCHEMBL2938937 0.83 PPARD (0.43) PPARDPPARATAS2R8ENPP2POLB
SCHEMBL2934030 0.83 PPARD (0.38) PPARDPPARAMAPTTAS2R8MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 PPARD 3189/4885PPARA 4338/4885MAPT 1554/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA PPARD 3572/4885PPARA 4692/4885MAPT 2136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.